Shore N, et al. – In this overview, researchers examined treatment decisions for metastatic castration–resistant prostate cancer (mCRPC). It was shown that increased use of chemohormonal therapy in castration–sensitive disease may influence subsequent treatment decisions in mCRPC. small, retrospective studies demonstrate cross–resistance between specific therapies in mCRPC. Larger prospective studies are needed.